6 results
The primary objective of this study is to investigate whether differences in patient specific pharmacokinetic properties, both dynamic and absolute, reveal the difference in response to lithium treatment. The pharmacokinetic properties which will be…
Our study tries to identify the ideal sclerosant dosage for the ClariVein® system in order to occlude the GSV permanently. By choosing the lowest dose with the same anatomical success rate, we achieve a safe treatment which also gives us the…
Objective: To evaluate the anatomical success of MOCA versus RFA in treatment of symptomatic insufficient SSV.
Primary:* To compare overall survival (OS) in subjects with advanced soft tissue sarcoma ([STS], one of two subtypes: adipocytic [ADI] or leiomyosarcoma [LMS]) when treated with eribulin (Arm A) or dacarbazine (Arm B).Secondary:* To compare…
Primary Objectives:* To compare overall survival (OS) of patients who receive NKTR-102given once every 21 days (q21d) to patients who receive Treatment ofPhysician*s Choice (TPC) selected from the following list of seven singleagentintravenous…
Primary: • Demonstrate superior efficacy (increased progression-free survival [PFS]) of MEK162 vs. physician*s choice of selected chemotherapies (liposomal doxorubicin, paclitaxel and topotecan)Key Secondary: • Demonstrate superior efficacy (…